Shares of OvaScience Inc. (NASDAQ:OVAS) have been assigned a consensus rating of “Hold” from the eight research firms that are currently covering the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.17.
Several research analysts have recently weighed in on the company. JPMorgan Chase & Co. lowered their target price on OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Friday, August 5th. JMP Securities reiterated a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Wednesday, August 10th. Finally, Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a report on Tuesday, July 12th.
Shares of OvaScience (NASDAQ:OVAS) traded up 0.15% during mid-day trading on Thursday, reaching $6.68. The company’s stock had a trading volume of 150,593 shares. The stock’s market cap is $237.55 million. The stock has a 50 day moving average of $7.03 and a 200-day moving average of $7.08. OvaScience has a one year low of $4.53 and a one year high of $15.39.
OvaScience (NASDAQ:OVAS) last issued its earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. OvaScience had a negative return on equity of 60.10% and a negative net margin of 13,906.35%. The business’s revenue for the quarter was up 530.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.64) EPS. On average, equities research analysts expect that OvaScience will post ($2.66) EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of OvaScience by 26.3% in the second quarter. FMR LLC now owns 5,171,816 shares of the company’s stock worth $26,945,000 after buying an additional 1,076,787 shares during the last quarter. Janus Capital Management LLC raised its stake in shares of OvaScience by 12.2% in the second quarter. Janus Capital Management LLC now owns 3,860,236 shares of the company’s stock worth $20,111,000 after buying an additional 419,592 shares during the last quarter. Orbis Allan Gray Ltd purchased a new stake in shares of OvaScience during the first quarter worth about $19,839,000. BlackRock Fund Advisors raised its stake in shares of OvaScience by 29.9% in the second quarter. BlackRock Fund Advisors now owns 1,256,143 shares of the company’s stock worth $6,545,000 after buying an additional 288,953 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of OvaScience by 36.9% in the second quarter. Vanguard Group Inc. now owns 1,133,517 shares of the company’s stock worth $5,905,000 after buying an additional 305,783 shares during the last quarter. 80.70% of the stock is currently owned by institutional investors.